Cargando…

A case of hereditary metachronous bilateral triple-negative breast cancer that was highly sensitive to carboplatin

A 52-year-old woman with a strong family history of breast cancer was diagnosed as having triple-negative breast cancer (TNBC) in her right breast. Neoadjuvant chemotherapy (NAC; four cycles of epirubicin/cyclophosphamide/5-fluorouracil) was performed, followed by breast-conserving surgery and axill...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Rongrong, Adachi, Kayo, Koyama, Yoichi, Orimoto, Kyoko, Okazaki, Miki, Asaoka, Mariko, Teraoka, Saeko, Ueda, Ai, Miyahara, Kana, Kawate, Takahiko, Kaise, Hiroshi, Yamada, Kimito, Sato, Eichi, Ishikawa, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046408/
https://www.ncbi.nlm.nih.gov/pubmed/33884162
http://dx.doi.org/10.1093/jscr/rjab018
_version_ 1783678843234549760
author Wu, Rongrong
Adachi, Kayo
Koyama, Yoichi
Orimoto, Kyoko
Okazaki, Miki
Asaoka, Mariko
Teraoka, Saeko
Ueda, Ai
Miyahara, Kana
Kawate, Takahiko
Kaise, Hiroshi
Yamada, Kimito
Sato, Eichi
Ishikawa, Takashi
author_facet Wu, Rongrong
Adachi, Kayo
Koyama, Yoichi
Orimoto, Kyoko
Okazaki, Miki
Asaoka, Mariko
Teraoka, Saeko
Ueda, Ai
Miyahara, Kana
Kawate, Takahiko
Kaise, Hiroshi
Yamada, Kimito
Sato, Eichi
Ishikawa, Takashi
author_sort Wu, Rongrong
collection PubMed
description A 52-year-old woman with a strong family history of breast cancer was diagnosed as having triple-negative breast cancer (TNBC) in her right breast. Neoadjuvant chemotherapy (NAC; four cycles of epirubicin/cyclophosphamide/5-fluorouracil) was performed, followed by breast-conserving surgery and axillary lymph node dissection. Histopathological analysis of the surgical specimens demonstrated a few focal tumor cells remaining in the stroma, but not a pathological complete response (pCR). Weekly paclitaxel was subsequently added to the treatment regimen. A total of 17 months after the adjuvant treatments, TNBC recurred in her left breast with massive lymph node metastasis. Because of the early recurrence after standard treatment, NAC was administered together with carboplatin and paclitaxel. Histopathological analysis of the partially resected breast and axillary lymph nodes demonstrated a pCR. No recurrent disease was found 2 years after the second TNBC treatment. This case underlines the importance of platinum-based chemotherapy and prophylactic mastectomy for patients with BRCA dysfunction.
format Online
Article
Text
id pubmed-8046408
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-80464082021-04-20 A case of hereditary metachronous bilateral triple-negative breast cancer that was highly sensitive to carboplatin Wu, Rongrong Adachi, Kayo Koyama, Yoichi Orimoto, Kyoko Okazaki, Miki Asaoka, Mariko Teraoka, Saeko Ueda, Ai Miyahara, Kana Kawate, Takahiko Kaise, Hiroshi Yamada, Kimito Sato, Eichi Ishikawa, Takashi J Surg Case Rep Case Report A 52-year-old woman with a strong family history of breast cancer was diagnosed as having triple-negative breast cancer (TNBC) in her right breast. Neoadjuvant chemotherapy (NAC; four cycles of epirubicin/cyclophosphamide/5-fluorouracil) was performed, followed by breast-conserving surgery and axillary lymph node dissection. Histopathological analysis of the surgical specimens demonstrated a few focal tumor cells remaining in the stroma, but not a pathological complete response (pCR). Weekly paclitaxel was subsequently added to the treatment regimen. A total of 17 months after the adjuvant treatments, TNBC recurred in her left breast with massive lymph node metastasis. Because of the early recurrence after standard treatment, NAC was administered together with carboplatin and paclitaxel. Histopathological analysis of the partially resected breast and axillary lymph nodes demonstrated a pCR. No recurrent disease was found 2 years after the second TNBC treatment. This case underlines the importance of platinum-based chemotherapy and prophylactic mastectomy for patients with BRCA dysfunction. Oxford University Press 2021-04-14 /pmc/articles/PMC8046408/ /pubmed/33884162 http://dx.doi.org/10.1093/jscr/rjab018 Text en Published by Oxford University Press and JSCR Publishing Ltd. All rights reserved. © The Author(s) 2021. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Wu, Rongrong
Adachi, Kayo
Koyama, Yoichi
Orimoto, Kyoko
Okazaki, Miki
Asaoka, Mariko
Teraoka, Saeko
Ueda, Ai
Miyahara, Kana
Kawate, Takahiko
Kaise, Hiroshi
Yamada, Kimito
Sato, Eichi
Ishikawa, Takashi
A case of hereditary metachronous bilateral triple-negative breast cancer that was highly sensitive to carboplatin
title A case of hereditary metachronous bilateral triple-negative breast cancer that was highly sensitive to carboplatin
title_full A case of hereditary metachronous bilateral triple-negative breast cancer that was highly sensitive to carboplatin
title_fullStr A case of hereditary metachronous bilateral triple-negative breast cancer that was highly sensitive to carboplatin
title_full_unstemmed A case of hereditary metachronous bilateral triple-negative breast cancer that was highly sensitive to carboplatin
title_short A case of hereditary metachronous bilateral triple-negative breast cancer that was highly sensitive to carboplatin
title_sort case of hereditary metachronous bilateral triple-negative breast cancer that was highly sensitive to carboplatin
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046408/
https://www.ncbi.nlm.nih.gov/pubmed/33884162
http://dx.doi.org/10.1093/jscr/rjab018
work_keys_str_mv AT wurongrong acaseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT adachikayo acaseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT koyamayoichi acaseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT orimotokyoko acaseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT okazakimiki acaseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT asaokamariko acaseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT teraokasaeko acaseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT uedaai acaseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT miyaharakana acaseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT kawatetakahiko acaseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT kaisehiroshi acaseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT yamadakimito acaseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT satoeichi acaseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT ishikawatakashi acaseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT wurongrong caseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT adachikayo caseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT koyamayoichi caseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT orimotokyoko caseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT okazakimiki caseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT asaokamariko caseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT teraokasaeko caseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT uedaai caseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT miyaharakana caseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT kawatetakahiko caseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT kaisehiroshi caseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT yamadakimito caseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT satoeichi caseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin
AT ishikawatakashi caseofhereditarymetachronousbilateraltriplenegativebreastcancerthatwashighlysensitivetocarboplatin